Immune Response to Biofilm Growing Pulmonary Infection

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Sep 23

PMID 36140163

Authors

Kim Thomsen

Niels Hoiby

Peter Ostrup Jensen

Oana Ciofu

Claus Moser

Affiliations

Soon will be listed here.

Abstract

Biofilm infections are tolerant to the host responses and recalcitrance to antibiotic drugs and disinfectants. The induced host-specific innate and adaptive immune responses by established biofilms are significantly implicated and contributes to the course of the infections. Essentially, the host response may be the single one factor impacting the outcome most, especially in cases where the biofilm is caused by low virulent opportunistic bacterial species. Due to the chronicity of biofilm infections, activation of the adaptive immune response mechanisms is frequently experienced, and instead of clearing the infection, the adaptive response adds to the pathogenesis. To a high degree, this has been reported for chronic lung infections, where both a pronounced antibody response and a skewed Th1/Th2 balance has been related to a poorer outcome. In addition, detection of an adaptive immune response can be used as a significant indicator of a chronic lung infection and is included in the clinical definitions as such. Those issues are presented in the present review, along with a characterization of the airway structure in relation to immune responses towards pulmonary infections.

Citing Articles

Global challenges and microbial biofilms: Identification of priority questions in biofilm research, innovation and policy.

Coenye T, Ahonen M, Anderson S, Camara M, Chundi P, Fields M Biofilm. 2024; 8:100210.

PMID: 39221168 PMC: 11364012. DOI: 10.1016/j.bioflm.2024.100210.

Optimization of an in vitro Pseudomonas aeruginosa Biofilm Model to Examine Antibiotic Pharmacodynamics at the Air-Liquid Interface.

Tan X, Huang Y, Rana A, Singh N, Abbey T, Chen H NPJ Biofilms Microbiomes. 2024; 10(1):16.

PMID: 38429317 PMC: 10907394. DOI: 10.1038/s41522-024-00483-y.

Host-microbe interactions in chronic rhinosinusitis biofilms and models for investigation.

Vanderpool E, Rumbaugh K Biofilm. 2023; 6:100160.

PMID: 37928619 PMC: 10622848. DOI: 10.1016/j.bioflm.2023.100160.

Bacterial Biofilm Formation on Biomaterials and Approaches to Its Treatment and Prevention.

Li P, Yin R, Cheng J, Lin J Int J Mol Sci. 2023; 24(14).

PMID: 37511440 PMC: 10380251. DOI: 10.3390/ijms241411680.

Perspective: The viscoelastic properties of biofilm infections and mechanical interactions with phagocytic immune cells.

Wells M, Schneider R, Bhattarai B, Currie H, Chavez B, Christopher G Front Cell Infect Microbiol. 2023; 13:1102199.

PMID: 36875516 PMC: 9978752. DOI: 10.3389/fcimb.2023.1102199.

References

Bayes H, Bicknell S, MacGregor G, Evans T . T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One. 2014; 9(2):e90263. PMC: 3937364. DOI: 10.1371/journal.pone.0090263. View

Painter R, Valentine V, Lanson Jr N, Leidal K, Zhang Q, Lombard G . CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry. 2006; 45(34):10260-9. PMC: 2931333. DOI: 10.1021/bi060490t. View

Kimbrell D, Beutler B . The evolution and genetics of innate immunity. Nat Rev Genet. 2001; 2(4):256-67. DOI: 10.1038/35066006. View

Hwang J, Randall T, Silva-Sanchez A . Inducible Bronchus-Associated Lymphoid Tissue: Taming Inflammation in the Lung. Front Immunol. 2016; 7:258. PMC: 4928648. DOI: 10.3389/fimmu.2016.00258. View

Millares L, Marti S, Ardanuy C, Linares J, Santos S, Dorca J . Specific IgA against in severe COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12:2807-2811. PMC: 5628678. DOI: 10.2147/COPD.S141701. View

Moser C, Johansen H, Song Z, Hougen H, Rygaard J, Hoiby N . Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS. 1997; 105(11):838-42. View

Hagner M, Albrecht M, Guerra M, Braubach P, Halle O, Zhou-Suckow Z . IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease. Eur Respir J. 2020; 57(6). DOI: 10.1183/13993003.00716-2019. View

Stockinger B, Veldhoen M . Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007; 19(3):281-6. DOI: 10.1016/j.coi.2007.04.005. View

Ciofu O, Bagge N, Hoiby N . Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS. 2003; 110(12):881-91. DOI: 10.1034/j.1600-0463.2002.1101207.x. View

10.

Moser C, Jensen P, Kobayashi O, Hougen H, Song Z, Rygaard J . Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol. 2002; 127(2):206-13. PMC: 1906339. DOI: 10.1046/j.1365-2249.2002.01731.x. View

11.

Moser C, Jensen P, Thomsen K, Kolpen M, Rybtke M, Lauland A . Immune Responses to Biofilm Infections. Front Immunol. 2021; 12:625597. PMC: 7937708. DOI: 10.3389/fimmu.2021.625597. View

12.

Armstrong D, Hook S, Jamsen K, Nixon G, Carzino R, Carlin J . Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005; 40(6):500-10. DOI: 10.1002/ppul.20294. View

13.

Salomonsen C, Chriel M, Jensen T, Rangstrup-Christensen L, Hoiby N, Hammer A . Effect of infectious dose and season on development of hemorrhagic pneumonia in mink caused by Pseudomonas aeruginosa. Can J Vet Res. 2013; 77(3):221-5. PMC: 3700449. View

14.

Silver R, Myers A, Jarvela J, Flynn J, Rutledge T, Bonfield T . Diversity of Human and Macaque Airway Immune Cells at Baseline and during Tuberculosis Infection. Am J Respir Cell Mol Biol. 2016; 55(6):899-908. PMC: 5248955. DOI: 10.1165/rcmb.2016-0122OC. View

15.

Thomsen K, Christophersen L, Bjarnsholt T, Jensen P, Moser C, Hoiby N . Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils. Infect Immun. 2015; 83(7):2686-93. PMC: 4468541. DOI: 10.1128/IAI.02970-14. View

16.

Schiotz P, Sorensen H, Hoiby M . Activated complement in the sputum from patients with cystic fibrosis. Acta Pathol Microbiol Scand C. 1979; 87C(1):1-5. View

17.

Faure E, Kwong K, Nguyen D . in Chronic Lung Infections: How to Adapt Within the Host?. Front Immunol. 2018; 9:2416. PMC: 6204374. DOI: 10.3389/fimmu.2018.02416. View

18.

Kalinski P, Hilkens C, Wierenga E, Kapsenberg M . T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999; 20(12):561-7. DOI: 10.1016/s0167-5699(99)01547-9. View

19.

Collin A, Lecocq M, Noel S, Detry B, Carlier F, Aboubakar Nana F . Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine. 2020; 60:102974. PMC: 7495088. DOI: 10.1016/j.ebiom.2020.102974. View

20.

Nilsson E, Kollberg H, Johannesson M, Wejaker P, Carlander D, Larsson A . More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J Med Food. 2007; 10(2):375-8. DOI: 10.1089/jmf.2006.214. View